Global Leukemia Therapeutics Market 2016-2020

Publisher Name :
Date: 20-Sep-2016
No. of pages: 110
Inquire Before Buying

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

The analysts forecast global leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • F. Hoffmann-La Roche

  • Novartis

  • Bristol-Myers Squibb

  • AbbVie

  • Teva Pharmaceuticals


Other prominent vendors


  • Altor BioScience

  • Amgen

  • ARIAD Pharmaceuticals

  • Arno Therapeutics

  • Astex Pharmaceuticals

  • AstraZeneca

  • Baxter Healthcare

  • Bayer HealthCare

  • Bellicum Pharmaceuticals

  • Biogen

  • Boehringer Ingelheim

  • BioLineRx

  • Boston Biomedical

  • Celator Pharmaceuticals

  • Celgene

  • CTI BioPharma

  • Chroma Therapeutics

  • Chugai Pharmaceutical

  • Cyclacel Pharmaceuticals

  • Daiichi Sankyo

  • Eisai

  • Emergent BioSolutions

  • Erytech Pharma

  • Fate Therapeutics

  • Genzyme

  • Gilead Sciences

  • GlaxoSmithKline

  • iDD biotech

  • Immune Pharmaceuticals

  • Immunomedics

  • Infinity Pharmaceuticals

  • Innate Pharma

  • Jazz Pharmaceuticals

  • Juno Therapeutics

  • Karyopharm Therapeutics

  • Ligand Pharmaceuticals

  • MEDA Pharmaceuticals

  • MedImmune

  • Merck

  • Midas Pharma

  • Molecular Templates

  • MorphoSys

  • Nippon Shinyaku

  • Novo Nordisk

  • Onconova Therapeutics

  • Ono Pharmaceuticals

  • Orphan Europe

  • Otsuka

  • Pfizer

  • Portola Pharmaceuticals

  • Regeneron Pharmaceuticals

  • Sanofi

  • Sigma-Tau Pharmaceuticals

  • Stemline Therapeutics

  • Sunesis Pharmaceuticals

  • TG Therapeutics

  • TheraMAB

  • Tolero Pharmaceuticals

  • XEME Biopharma

  • Xencor

  • ZIOPHARM Oncology


Market driver


  • Technological advances in the monitoring of leukemia

  • For a full, detailed list, view our report


Market challenge


  • Limitations associated with current therapeutic options

  • For a full, detailed list, view our report


Market trend


  • Rise in the development of combination therapies

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global Leukemia Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market
Market overview
Total addressable market for global CLL therapeutics
Vendors in the market

PART 09: Global ALL therapeutics market
Market overview
Vendors in the market

PART 10: Global AML therapeutics market
Market overview
Vendors in the market

PART 11: Global CML therapeutics market
Market overview
Vendors in the market

PART 12: Geographical segmentation
Global leukemia therapeutics market by geography 2015-2020
Leukemia therapeutics market in Americas
Leukemia therapeutics market in EMEA
Leukemia therapeutics market in APAC

PART 13: Market drivers
Special regulatory designations for drugs
Technological advances in the monitoring of leukemia
Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges
Complicated disease prognosis
Financial and infrastructural constraints
Limitations associated with current therapeutic options
Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends
Rise in the development of combination therapies
Patient assistance programs
Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape
Competitive scenario
Other prominent vendors

PART 19: Key vendor analysis
F. Hoffmann-La Roche
Novartis
Bristol-Myers Squibb
AbbVie
Teva Pharmaceuticals

PART 20: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for global leukemia therapeutics market 2015
Exhibit 05: Pipeline portfolio: Global CLL therapeutics market
Exhibit 06: Pipeline portfolio: Global CML therapeutics market
Exhibit 07: Pipeline portfolio: Global ALL therapeutics market
Exhibit 08: Pipeline portfolio: Global AML therapeutics market
Exhibit 09: Global leukemia therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Distribution of people aged 60 years and over (millions)
Exhibit 11: Global leukemia therapeutics market 2015-2020 ($ billions)
Exhibit 12: Global leukemia therapeutics market segmentation: Growth cycle analysis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global leukemia therapeutics market by type of disease 2015
Exhibit 15: Global leukemia therapeutics market by type of disease 2015-2020
Exhibit 16: Global leukemia therapeutics market segmentation: Growth lifecycle analysis
Exhibit 17: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 18: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 19: Major vendors in the CLL therapeutics market 2015
Exhibit 20: Global ALL therapeutics market 2015-2020 ($ billions)
Exhibit 21: Major vendors in ALL therapeutics market 2015
Exhibit 22: Global AML therapeutics market 2015-2020 ($ millions)
Exhibit 23: Major vendors in global AML therapeutics market
Exhibit 24: Global CML therapeutics market 2015-2020 ($ billions)
Exhibit 25: Major vendors in global CML therapeutics market
Exhibit 26: Global leukemia therapeutics market by geography 2015-2020
Exhibit 27: Percentage share of global leukemia therapeutics market by geography 2015 and 2020
Exhibit 28: Global share of leukemia therapeutics market by geography 2015
Exhibit 29: Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30: Revenue/growth outlook in different countries/regions 2015
Exhibit 31: Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 32: Leukemia therapeutics market in different regions by type of disease
Exhibit 33: Opportunity analysis of leukemia therapeutics market in Americas
Exhibit 34: Percentage share of new cases of leukemia in US 2014
Exhibit 35: Hispanic population percentage in US total population
Exhibit 36: Leukemia therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of leukemia therapeutics market in EMEA
Exhibit 38: Leukemia therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Opportunity analysis of leukemia therapeutics market in APAC
Exhibit 40: Leukemia therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 41: Orphan designation pipeline drugs for leukemia
Exhibit 42: Breakthrough therapy designation drugs for leukemia
Exhibit 43: Expanded indication approval drugs in the treatment of leukemia
Exhibit 44: Impact of drivers
Exhibit 45: Cost of therapy for some leukemia drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under development for the treatment of leukemia
Exhibit 48: Leukemia drugs with patient assistance programs
Exhibit 49: Key vendors ranking 2015
Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015
Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
Exhibit 52: F. Hoffmann-La Roche: Profile
Exhibit 53: F. Hoffmann-La Roche: Strength analysis
Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
Exhibit 58: Novartis: Profile
Exhibit 59: Novartis: Strength analysis
Exhibit 60: Novartis: Growth strategy matrix
Exhibit 61: Novartis: Opportunity assessment
Exhibit 62: Bristol-Myers Squibb: Profile
Exhibit 63: Bristol-Myers Squibb: Strength analysis
Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix
Exhibit 65: Bristol-Myers Squibb: Opportunity assessment
Exhibit 66: AbbVie: Profile
Exhibit 67: AbbVie: Strength analysis
Exhibit 68: AbbVie: Growth strategy matrix
Exhibit 69: AbbVie: Opportunity assessment
Exhibit 70: Teva Pharmaceuticals: Profile
Exhibit 71: Teva Pharmaceuticals: Strength analysis
Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix
Exhibit 73: Teva Pharmaceuticals: Opportunity assessment
Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)

  • Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023
    Published: 24-Mar-2017        Price: US 4950 Onwards        Pages: 132
    Summary DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics mar......
  • Oral Mucositis - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 91
    Oral Mucositis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape. Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the inte......
  • Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 88
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, dr......
  • Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 107
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Neutropenia (Oncology) pipeline landscape.Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and ab......
  • Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017
    Published: 01-Mar-2017        Price: US 2450 Onwards        Pages: 90
    DelveInsight's, "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017", report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrog......
  • Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017
    Published: 01-Mar-2017        Price: US 2450 Onwards        Pages: 90
    DelveInsight's, "Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017", report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the ovarian cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Ovarian Cancer which mainly describes the treatment of ovarian cancer ......
  • Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017
    Published: 01-Mar-2017        Price: US 2750 Onwards        Pages: 365
    DelveInsight's, "Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen ......
  • Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 470
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Personalized Medicine in Oncology Partneri......
  • Global Mucositis Partnering 2010-2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the mucositis partnering deals and agreements entered into by the worlds leading healthcare companies Description The Global Mucositis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs